drugset / Trial / NCT00895089

Moxifloxacin Versus Ceftriaxone in the Treatment of Primary Pyogenic Liver Abscess

NCT00895089

RandomizedParallel-groupOpen-labelTreatment

Summary

This clinical trial compares the use of moxifloxacin versus ceftriaxone in the treatment of primary pyogenic liver abscess. The trial will include nonpregnant adults presenting with primary liver abscess based on clinical diagnosis and computed tomography. The trial aims to determine whether the use of moxifloxacin can effectively treat primary pyogenic liver abscess and shorten hospitalization. This regimen has the additional benefit of avoiding nephrotoxic agents, such as aminoglycosides, used frequently in treatment of pyogenic liver abscess. Development of antibiotic resistance to colonized bacteria in the gastrointestinal tract will also be evaluated using stool cultures.

Timeline

Start
2009-05
Primary completion
2010-12
Completion
2011-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator CEPHALEXIN ANHYDROUS Small molecule 1 g Oral
Comparator Ceftriaxone Other / unclassified 2 g Intravenous
Subject Moxifloxacin Small molecule 400 mg Intravenous